Vor Biopharma Inc. (VOR)
NasdaqGS · USD · Healthcare · Biotechnology
$18.33 (+0.38%) as of
Key statistics
- Market cap
- 1.08B
- P/E (TTM)
- 0.10
- Forward P/E
- -5.00
- EPS (TTM)
- 181.07
- Dividend yield
- 0.00%
- 52-week range
- 6.50 – 28.66
- Beta
- 1.78
- Profit margin
- 0.00%
- Analyst target
- $39.00
- Volume
- 470.34k
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 76
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.